These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 19008470)

  • 1. Dysregulated RANK ligand/RANK axis in hyperhomocysteinemic subjects: effect of treatment with B-vitamins.
    Nenseter MS; Ueland T; Retterstøl K; Strøm E; Mørkrid L; Landaas S; Ose L; Aukrust P; Holven KB
    Stroke; 2009 Jan; 40(1):241-7. PubMed ID: 19008470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired inhibitory effect of interleukin-10 on the balance between matrix metalloproteinase-9 and its inhibitor in mononuclear cells from hyperhomocysteinemic subjects.
    Holven KB; Halvorsen B; Bjerkeli V; Damås JK; Retterstøl K; Mørkrid L; Ose L; Aukrust P; Nenseter MS
    Stroke; 2006 Jul; 37(7):1731-6. PubMed ID: 16728689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cystatin C levels in plasma and peripheral blood mononuclear cells among hyperhomocysteinaemic subjects: effect of treatment with B-vitamins.
    Tobin KA; Holven KB; Retterstøl K; Strøm E; Ose L; Aukrust P; Nenseter MS
    Br J Nutr; 2009 Dec; 102(12):1783-9. PubMed ID: 19682403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease.
    Liu W; Feng W; Wang F; Li W; Gao C; Zhou B; Ma M
    Exp Mol Pathol; 2008 Jun; 84(3):213-7. PubMed ID: 18417124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
    Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
    Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of 2-year vitamin B12 and folic acid supplementation in hyperhomocysteinemic elderly on arterial stiffness and cardiovascular outcomes within the B-PROOF trial.
    van Dijk SC; Enneman AW; Swart KM; van Wijngaarden JP; Ham AC; Brouwer-Brolsma EM; van der Zwaluw NL; Blom HJ; Feskens EJ; Geleijnse JM; van Schoor NM; Dhonukshe-Rutten RA; de Jongh RT; Lips P; de Groot LC; Uitterlinden AG; Smulders YM; van den Meiracker AH; Mattace Raso FU; van der Velde N
    J Hypertens; 2015 Sep; 33(9):1897-906; discussion 1906. PubMed ID: 26147383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor activator of nuclear factor kappa B ligand (RANKL) modulates the expression of genes involved in apoptosis and cell cycle in human osteoclasts.
    Rimondi E; Zweyer M; Ricci E; Fadda R; Secchiero P
    Anat Rec (Hoboken); 2007 Jul; 290(7):838-45. PubMed ID: 17506059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid treatment reduces chemokine release from peripheral blood mononuclear cells in hyperhomocysteinemic subjects.
    Holven KB; Aukrust P; Holm T; Ose L; Nenseter MS
    Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):699-703. PubMed ID: 11950713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor activator of nuclear factor-κB ligand is a novel inducer of myocardial inflammation.
    Ock S; Ahn J; Lee SH; Park H; Son JW; Oh JG; Yang DK; Lee WS; Kim HS; Rho J; Oh GT; Abel ED; Park WJ; Min JK; Kim J
    Cardiovasc Res; 2012 Apr; 94(1):105-14. PubMed ID: 22298642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
    Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
    Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperhomocysteinemic subjects have enhanced expression of lectin-like oxidized LDL receptor-1 in mononuclear cells.
    Holven KB; Scholz H; Halvorsen B; Aukrust P; Ose L; Nenseter MS
    J Nutr; 2003 Nov; 133(11):3588-91. PubMed ID: 14608078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid reduces chemokine MCP-1 release and expression in rats with hyperhomocystinemia.
    Li M; Chen J; Li YS; Feng YB; Zeng QT
    Cardiovasc Pathol; 2007; 16(5):305-9. PubMed ID: 17868882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients.
    Marcucci R; Zanazzi M; Bertoni E; Rosati A; Fedi S; Lenti M; Prisco D; Castellani S; Abbate R; Salvadori M
    Transplantation; 2003 May; 75(9):1551-5. PubMed ID: 12792513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of multivitamin supplementation on the homocysteine and methylmalonic acid blood concentrations in women over the age of 60 years.
    Wolters M; Hermann S; Hahn A
    Eur J Nutr; 2005 Mar; 44(3):183-92. PubMed ID: 15309436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of B vitamins in lowering homocysteine in older men: maximal effects for those with B12 deficiency and hyperhomocysteinemia.
    Flicker L; Vasikaran SD; Thomas J; Acres JM; Norman P; Jamrozik K; Hankey GJ; Almeida OP
    Stroke; 2006 Feb; 37(2):547-9. PubMed ID: 16373648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of response to treatment with supraphysiologic doses of B-vitamins in hyperhomocysteinemic hemodialysis patients.
    Nakhoul F; Abassi Z; Plawner M; Khankin E; Ramadan R; Lanir N; Brenner B; Green J
    Isr Med Assoc J; 2004 Apr; 6(4):213-7. PubMed ID: 15115259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of B-vitamins on biochemical bone turnover markers and bone mineral density in osteoporotic patients: a 1-year double blind placebo controlled trial.
    Herrmann M; Umanskaya N; Traber L; Schmidt-Gayk H; Menke W; Lanzer G; Lenhart M; Peter Schmidt J; Herrmann W
    Clin Chem Lab Med; 2007; 45(12):1785-92. PubMed ID: 18020969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization.
    Sandberg WJ; Yndestad A; Øie E; Smith C; Ueland T; Ovchinnikova O; Robertson AK; Müller F; Semb AG; Scholz H; Andreassen AK; Gullestad L; Damås JK; Frøland SS; Hansson GK; Halvorsen B; Aukrust P
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):857-63. PubMed ID: 16424351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure.
    Ueland T; Yndestad A; Øie E; Florholmen G; Halvorsen B; Frøland SS; Simonsen S; Christensen G; Gullestad L; Aukrust P
    Circulation; 2005 May; 111(19):2461-8. PubMed ID: 15883214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interrelationship of circulating matrix metalloproteinase-9, TNF-α, and OPG/RANK/RANKL systems in COPD patients with osteoporosis.
    Zhang PF; Pan L; Luo ZY; Zhao HJ; Cai SX
    COPD; 2013 Dec; 10(6):650-6. PubMed ID: 23845033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.